Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to enroll 128 patients, remains on track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026. Sept. 03, 2025 -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neu

Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trials JADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile preclinically, supporting the potential for patient-friendly subcutaneous dosing every eight weeks or longer Interim, biomarker-rich Phase 1 healthy volunteer data are expected in the first half of 2026, and are anticipated to define dose and dosing interval selection based on biomarker resp

Open-label study in as few as 16 tumor hyperinsulinism (HI) patients Study initiated and enrolling patients in the U.S. and Europe Topline data expected in the second half of 2026 Sept. 02, 2025 -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that the Company has gained alignment with FDA on a significantly streamlined clinical development path for its ongoing Phase 3 s

September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient setting Adverse event profile and efficacy were consistent with previously reported studies in R/R DLBCL patients Data also demonstrated 64.3% overall response rate with a complete respon

Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain at 12 Weeks vs −5.4% Mean Weight Loss on Placebo Safety Results Showed ART27.13 was Well Tolerated Sept. 03, 2025 -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathway

Sept. 02, 2025 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that an oral presentation of Phase 2 data in post-surgical hypoparathyroidism and two poster sessions on skeletal dysplasia data will be shared at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2025, taking place in Seattle, WA from September 5 - 8, 2025. The Oral Calcilytic Encaleret Reduced Urina

Sept. 02, 2025 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post-hoc analysis (“Efficacy of Sotagliflozin Among Older Adults: A Pooled Analysis of SCORED and SOLOIST-WHF”) of clinical data was presented Sunday, August 31, during an oral presentation at the European Society of Cardiology (ESC) 2025 Congress in Madrid, Spain. It is well-established that the incidence of stroke and myocardial infarction (MI, or heart attack), known collectively as major cardiovascular adverse

Start of the phase 1b trial in a new indication expands Step Pharma’s clinical programme, building on the development of dencatistat in lymphoma and solid tumours This milestone marks the third indication for dencatistat, a first-in-class, highly selective, orally available CTPS1 inhibitor, demonstrating its versatility as a "pipeline in a product" 2 September 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announced that the first

Sept. 02, 2025 -- PolarityBio, a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative skin multicellular therapy, today announced the launch of an Expanded Access Treatment Protocol (EAP) to provide continued access to SkinTE® for patients with Wagner 1 diabetic foot ulcers (DFUs). The FDA cleared PolarityBio to initiate this protocol following the successful completion of enrollment in the company’s pivotal Phase

Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis 2 September 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), today announces that the first patient has been successfully dosed in its Phase IIa clinical trial “Citydream”. The trial will evaluate CIT-013, a first-in-cla